Page 4 - Ping Cao News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ping cao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ping Cao Today - Breaking & Trending Today

BridGene Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BridGene Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Lisa Sher , Dave Schemelia , Bridgene Biosciences , Bridgene Biosciences Inc , Ping Cao Co , Irene Yuan , Executive Vice President , Annual Global Investment Conference , Isobaric Mass Tagged Affinity Characterization , Ping Cao , Chief Executive Officer , Annual Global Investment ,

BridGene Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BridGene Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Lisa Sher , Dave Schemelia , Bridgene Biosciences , Bridgene Biosciences Inc , Ping Cao Co , Irene Yuan , Executive Vice President , Annual Global Investment Conference , Isobaric Mass Tagged Affinity Characterization , Ping Cao , Chief Executive Officer , Annual Global Investment ,

Queensland man who dissolved wife's body in wheelie bin of acid is applying for parole

A Queensland man who dissolved his wife s body in a wheelie-bin of acid after murdering her is applying for parole after serving less than 10 years in jail. ....

Klaus Andres , Ping Cao , German Born Andres , Parole Board , கிளாஸ் அன்றேல் , பரோல் பலகை ,

BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company's Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs


BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company s Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs
News provided by
Share this article
Share this article
SUNNYVALE, Calif., May 5, 2021 /PRNewswire/  BridGene Biosciences, Inc., a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules for high value, yet traditionally undruggable targets, announced today it has raised $12 million in a Series A private financing round led by Wedo Venture Partners with additional participation by Kaitai Capital and Takeda Ventures, alongside existing investor Pangu Venture.
BridGene plans to use proceeds from the Series A financing to expand the company s proprietary covalent library to discover small-molecule ligands for a broader range of targets, advance existing oncology programs and enhance operations.  ....

Miriam Weber Miller , Johanna Bennett , Leilei Wang , Bridgene Biosciences , Bridgene Biosciences Inc , Wedo Venture Partners , Kaitai Capital , Takeda Ventures , Isobaric Mass Tagged Affinity Characterization , Wedo Venture , Ping Cao , Weber Miller , மிரியம் வெபர் மில்லர் , ஜோஹன்னா பென்னட் , டாகேடா முயற்சிகள் , வெபர் மில்லர் ,

Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene


Published: May 05, 2021
By Mark Terry
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
Esker Launches with $70 Million Series A
San Francisco-based Esker Therapeutics, a Foresite Labs-incubated company,
launched with a $70 million Series A financing. The round was led by Foresite Capital. The company focuses on autoimmune diseases and so-called precision therapies that target patients most likely to benefit from them.
The company’s precision analytics platform is powered by Foresite Labs. The technology platform is made up of high-quality curated genetic, clinical and medical record data, a systems immunology approach for prospective data collections and tools for building patient registries. Its lead pipeline product is ESK-001, a highly selective TYK2 inhibitor with greater selectivity for TYK2 over JAK1, initially in development for psoriasis. It is ....

United Kingdom , North Carolina , United States , Duke University , Jonathan Milner , Kelli Luginbuhl , June Lee , Ashutosh Chilkoti , Joe Mcmahon , Isolere Bio , Darrinm Disley , Carolina Biotech Center , National Institutes Of Health , National Science Foundation , Esker Therapeutics , Foresite Labs Incubated , Mogrify Limited , Parkwalk Advisors , Astellas Venture Management , Jonathan Miler , Bio Raises , National Institutes , North Carolina Biotech , Gene Closes , California Based Bridgene , Wedo Venture Partners ,